Who was studied?
One patient with HER2-expressing metastatic pancreatic ductal adenocarcinoma.
What does the publication report?
A partial response, 6.5 months of PFS and 14.2 months of OS were reported.
Safety findings
No grade 2 or higher treatment-related events were reported in this patient.
How should we interpret it?
A single patient cannot establish efficacy or predict an individual outcome. Prior and concurrent treatments limit attribution.
Read the original source
This independently written summary was checked against the publicly available abstract. It is not a translation of the full paper or a clinical recommendation.
PRaG 3.0 therapy for human epidermal growth factor receptor 2-positive metastatic pancreatic ductal adenocarcinoma: A case report · DOI: 10.3748/wjg.v30.i9.1237 · PMID: 38577174
Educational reporting, not individualized medical advice. Discuss treatment decisions with your clinical team.